EDSA Company Profile and Key Details

EDSA has shown mixed momentum, losing -1.35% over the past week and -38.07% over the past quarter, though year-to-date performance is up 2.82%. Short-term trend indicators are bullishly aligned (SMA20 22.61%, SMA50 2.56%, SMA200 -30.24%). The stock’s 14-day RSI is 56.88 (neutral), while the ATR of 0.2 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -53.92% below its high and over 88.89% above its low. Average 10-day trading volume of 14.86 million shares is significantly above the 3-month average of 1.77 million, indicating heightened recent market interest.

Edesa Biotech, Inc. has 7.04 million shares outstanding. The public float is 4.28 million shares, elevated short interest at 0.12% of float. This equals 7.09 thousand shares. The short ratio is 0.26 days. Institutional investors hold 41.92% of the float. Insiders own 28.55%. Pardeep Nijhawan Medicine Professional Corp holds 594.81 thousand shares, Nijhawan Pardeep has 341.70 thousand shares and van der Velden Peter has 150.28 thousand shares.

Edesa Biotech, Inc. generated EPS of -$1.15 over the past year. Five-year average earnings growth is -11.35%. Wall Street analysts project EPS growth of -1.04% annually over the next five years. The latest quarter delivered EPS of -$0.32. The next quarter is forecast at -$0.26. Next year's EPS is expected at $59.29. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $21.00 to $5.00. The high target offers 1444.12% upside. The low target suggests 267.65% downside. The mean target is $10.33. This offers 659.56% upside. Edesa Biotech, Inc. earnings surprise history is a mixed track record. The quarter that ended December 12, 2025, missed forecasts by 18.52%. The prior quarter beat by -3.85%. Over the last six quarters, Apple has recorded several small beats. These include -10.34% in August 09, 2024.

Edesa Biotech, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.90. This means the shares are trading below this model’s fair value.

Edesa Biotech, Inc. (NASDAQ:EDSA) closed at $1.36 USD, losing -$0.15 (-9.93%) from the previous close of $1.51. The stock is currently mid-range between its 52-week high and low $0.72 and $2.95. With a market capitalization of about $11.35 million, Edesa Biotech, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.21). Key stats such as the average daily volume over the past year has been around 162.90 thousand shares, trading with heavier-than-usual volume. Headquartered in Markham, ON, Edesa Biotech, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Pardeep Nijhawan, the company employs approximately 16 people and listed since June 21, 2010. Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs.

Edesa Biotech, Inc. trades at a P/E ratio of -1.36, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.76 suggesting the stock is closer to book value. The P/FCF stands at -1.41, also above market averages.

Our AI price prediction model suggests that Edesa Biotech, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -23.53%, with price expected at $1.04 by March 10, 2026, within a range of $0.91 to $1.16 3-Month Outlook: Projected fall of -59.56%, reaching $0.55 by May 25, 2026, with a range of $0.45 to $0.63. 1-Year Outlook: Projected gain of 11.76%, with price at $1.52 by February 24, 2027, within a range of $0.07 to $1.24.

Edesa Biotech, Inc. (NASDAQ:EDSA) shares are flat 2.82% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Edesa Biotech, Inc. trading at a premium to the broader market with a P/E of -1.36. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $18.80, suggesting 1282.35% upside. Our AI forecast model points to short-term weakness (-23.53% over two weeks), a medium-term fall (-59.56% over three months), and a longer-term gain (11.76% over one year), with expected trading ranges indicating moderate volatility.